Growth and endocrinopathies among children with β-Thalassemia major treated at Dubai Thalassemia centre

Abstract Background β-Thalassemia major (BTM) is one of the most common hereditary anemias worldwide. Patients suffer from iron overload that results from repeated blood transfusion This in turn leads to multiple organ damage and endocrinopathies. This study aims to assess the prevalence of growth r...

Full description

Bibliographic Details
Published in:	BMC Pediatrics
Main Authors:	Rabah Almahmoud, Amal Hussein, Fatheya Al Khaja, Ahmed Farrag Soliman, Hany Dewedar, Zainab Al Shareef, Sarah Mathai
Format:	Article
Language:	English
Published:	BMC 2024-04-01
Subjects:	Thalassemia Endocrinopathies Deferasirox Hypothryroidism Diabetes mellitus Growth delay
Online Access:	https://doi.org/10.1186/s12887-024-04670-w

Similar Items

Demographic and clinical profiles of patients with β-thalassemia major treated at Dubai Thalassemia Centre: A retrospective study
by: Rabah Almahmoud, et al.
Published: (2022-01-01)

Endocrinopathies in Turkish Children with Thalassemia Major
by: Belma Haliloğlu, et al.
Published: (2017-12-01)

Relationship Between Endocrinopathies and Ferritin Levels in Adult Turkish Patients with Beta Thalassemia Major: A Single-Center Experience
by: Gülsüm Akgun Çağlıyan, et al.
Published: (2020-12-01)

IRON CHELATION THERAPY IN THALASSEMIA SYNDROMES
by: Paolo Cianciulli
Published: (2009-06-01)

THE ANTIOXIDANT EFFECTS OF CAPPARIS OVATA AND DEFERASIROX IN PATIENTS WITH THALASSEMIA MAJOR
by: Handan Duman, et al.
Published: (2014-08-01)

Deferasirox in Indian children with thalassemia major: 3 years experience
by: Mayank Dhamija, et al.
Published: (2013-01-01)

Comparison of deferasirox and deferoxamine effects on iron overload and immunological changes in patients with blood transfusion-dependent β-thalassemia
by: Hayder M Al-Kuraishy, et al.
Published: (2017-01-01)

Renal function in patients with thalassemia major receiving Exjade® dispersible tablets and a new film-coated tablet formulation of deferasirox (Nanojade®)
by: Vahid Falahati, et al.
Published: (2022-01-01)

Investigating the Effect of Iron Chelation Therapy With Deferasirox on Liver Aminotransferases Levels in Transfusion-dependent β-thalassemia Patients
by: Shayan Pourkazem, et al.
Published: (2024-06-01)

THE RELATION BETWEEN TYPES OF IRON CHELATORS AND FERITIN ON OSTEOCALCIN OF THALASSEMIA PATIENTS WITH REPEATED TRANSFUSIONS
by: Sesa Amelia, et al.
Published: (2020-01-01)

LONG-TERM EFFECTIVENESS, SAFETY, AND TOLERABILITY OF TWICE-DAILY DOSING WITH DEFERASIROX IN CHILDREN WITH TRANSFUSION-DEPENDENT THALASSEMIAS UNRESPONSIVE TO STANDARD ONCE-DAILY DOSING
by: Jassada Buaboonnam, et al.
Published: (2021-10-01)

Prevalence of iron overload complications among patients with β-thalassemia major treated at Dubai Thalassemia Centre
by: Khawla Mohammed Belhoul, et al.
Published: (2013-01-01)

Use of Deferasirox Film-Coated Tablets in Pediatric Patients with Transfusion Dependent Thalassemia: A Single Center Experience
by: Alkistis Adramerina, et al.
Published: (2022-02-01)

Dutch-beta thalassemia: A rare mutation from India
by: Nirali Sanghvi, et al.
Published: (2022-09-01)

CLINICAL AND BIOCHEMICAL DATA OF ADULT THALASSEMIA MAJOR PATIENTS (TM) WITH MULTIPLE ENDOCRINE COMPLICATIONS (MEC) VERSUS TM PATIENTS WITH NORMAL ENDOCRINE FUNCTIONS: A RETROSPECTIVE LONG-TERM STUDY (40 YEARS) IN A TERTIARY CARE CENTER IN ITALY
by: Vincenzo De Sanctis, et al.
Published: (2016-04-01)

Lens opacity as a serious side effect following chelation therapy in beta thalassemia: A comparison between deferoxamine and deferasirox; randomized double-blinded clinical trial
by: Mohammad Reza Golpayegani, et al.
Published: (2019-01-01)

Comparison of Efficacy, Safety, and Humanistic Outcomes of Iron-Chelation Therapy in Pediatrics Suffering from Transfusion-Dependent β-Thalassemia Major
by: Narayana Goruntla, et al.
Published: (2020-07-01)

Combination iron chelation therapy with deferiprone and deferasirox in iron-overloaded patients with transfusiondependent β-thalassemia major
by: Hossein Karami, et al.
Published: (2017-01-01)

Efficacy and safety of deferasirox in pediatric patients of thalassemia at a Tertiary Care Teaching Hospital
by: Dhaval R Thakor, et al.
Published: (2017-01-01)

The COST-UTILITY ANALYSIS OF FOUR CHELATION REGIMENS FOR Β-THALASSEMIA MAJOR: A CHINESE PERSPECTIVE
by: Jialian Li
Published: (2020-04-01)

Risk Factors for Impaired Glucose Metabolism in Transfusion-Dependent Patients with β-Thalassemia: A Single-Center Retrospective Observational Study
by: Theodora Maria Venou, et al.
Published: (2025-01-01)

ECONOMIC EVALUATION OF CHELATION REGIMENS FOR β--THALASSEMIA MAJOR: A SYSTEMATIC REVIEW
by: Jialian Li
Published: (2019-06-01)

Bilateral Nuclear Cataract with Deferasirox in a Patient of Beta-thalassemia: A Case Report and Literature Review
by: Tushit Dhar, et al.
Published: (2024-04-01)

Stable Luminescent Poly(Allylaminehydrochloride)-Templated Copper Nanoclusters for Selectively Turn-Off Sensing of Deferasirox in β-Thalassemia Plasma
by: Hung-Ju Lin, et al.
Published: (2021-12-01)

Endocrinopathies and Male Infertility
by: Pallav Sengupta, et al.
Published: (2021-12-01)

Home isolation in transfusion-dependent thalassemia patients with SARS CoV2 infection: Experience from a developing country
by: Shruti Kakkar, et al.
Published: (2022-09-01)

DEFERASIROX: OVER A DECADE OF EXPERIENCE IN THALASSEMIA
by: Ali Taher
Published: (2018-11-01)

A pharmaco-economic evaluation of deferasirox for treating patients with iron overload caused by transfusion-dependent thalassemia in Taiwan
by: Wan-Ling Ho, et al.
Published: (2013-04-01)

Comparison of the effects of deferasirox film-coated tablets (Jadenu®) and deferasirox dispersible tablets (Exjade®) in patients with beta thalassemia major: a preliminary report of the effects on the satisfaction, convenience, cardiac/liver MRI T2*, serum ferritin level, and biochemical profiles
by: Mahya Mobinikhaledi, et al.
Published: (2024-11-01)

Paraneoplastic endocrinopathy in Castleman disease and POEMS syndrome
by: V. I. Odin, et al.
Published: (2020-10-01)

Challenges of Iron Chelation in Thalassemic Children
by: Alkistis Adramerina, et al.
Published: (2024-02-01)

Assessing the auditory effects of oral chelation therapy drug Deferasirox in individuals with β‐thalassemia major
by: Balwinder S. Tiwana, et al.
Published: (2024-12-01)

Poems syndrome: The rare endocrinopathy
by: Miletić Marija, et al.
Published: (2024-01-01)

Alopecia and Clinical Presentation of Endocrinopathies: Pathogenetic and Diagnostic Aspects
by: E. A. Praskurnichiy, et al.
Published: (2021-08-01)

Multiple endocrinopathies (growth hormone deficiency, autoimmune hypothyroidism and diabetes mellitus) in Kearns-Sayre syndrome
by: A. Berio, et al.
Published: (2013-06-01)

Markers of Fertility in Adolescents With Chronic Endocrinopathies at Transition From Paediatric to Adult Care
by: Daniela Choukair, et al.
Published: (2024-07-01)

Complex Clinical-Laboratory and Cytological Study of Cervical and Vaginal Discharge in Women with Endocrinopathies
by: V.H. Khoperiia, et al.
Published: (2015-05-01)

SEVERE LIVER IRON CONCENTRATIONS (LIC) IN 24 PATIENTS WITH Β-THALASSEMIA MAJOR: CORRELATIONS WITH SERUM FERRITIN, LIVER ENZYMES AND ENDOCRINE COMPLICATIONS
by: Vincenzo De Sanctis
Published: (2018-10-01)

Investigation of the incidence of Toxoplasmosis and cytomegalovirus in patients with thalassemia
by: Ali Yonis Saleh, et al.
Published: (2019-01-01)

Thalassemia
by: Tekin Aksu, et al.
Published: (2021-03-01)